PBBIF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of -- compared to Probi AB's net margin of -65.15%. Probi AB's return on equity of -- beat BioArctic AB's return on equity of 59.48%.

Probi AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Probi AB has higher upside potential than BioArctic AB, analysts believe Probi AB is more attractive than BioArctic AB.

Probi AB has a beta of 0.595, which suggesting that the stock is 40.504% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Probi AB has a quarterly dividend of $0.12 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Probi AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Probi AB quarterly revenues are --, which are smaller than BioArctic AB quarterly revenues of $14M. Probi AB's net income of -- is lower than BioArctic AB's net income of -$9.1M. Notably, Probi AB's price-to-earnings ratio is 263.33x while BioArctic AB's PE ratio is 32.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Probi AB is 6.03x versus 16.63x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -- compared to Probi AB's net margin of 33.97%. Probi AB's return on equity of -- beat Camurus AB's return on equity of 21.63%.

Probi AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Probi AB has higher upside potential than Camurus AB, analysts believe Probi AB is more attractive than Camurus AB.

Probi AB has a beta of 0.595, which suggesting that the stock is 40.504% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.438%.

Probi AB has a quarterly dividend of $0.12 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Probi AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Probi AB quarterly revenues are --, which are smaller than Camurus AB quarterly revenues of $59.6M. Probi AB's net income of -- is lower than Camurus AB's net income of $20.2M. Notably, Probi AB's price-to-earnings ratio is 263.33x while Camurus AB's PE ratio is 51.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Probi AB is 6.03x versus 17.29x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of -- compared to Probi AB's net margin of -481.29%. Probi AB's return on equity of -- beat Hansa Biopharma AB's return on equity of --.

Probi AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Probi AB has higher upside potential than Hansa Biopharma AB, analysts believe Probi AB is more attractive than Hansa Biopharma AB.

Probi AB has a beta of 0.595, which suggesting that the stock is 40.504% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.377%.

Probi AB has a quarterly dividend of $0.12 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Probi AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Probi AB quarterly revenues are --, which are smaller than Hansa Biopharma AB quarterly revenues of $3.2M. Probi AB's net income of -- is lower than Hansa Biopharma AB's net income of -$15.6M. Notably, Probi AB's price-to-earnings ratio is 263.33x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Probi AB is 6.03x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Vivesto AB has a net margin of -- compared to Probi AB's net margin of --. Probi AB's return on equity of -- beat Vivesto AB's return on equity of -23.44%.

Probi AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Vivesto AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Probi AB has higher upside potential than Vivesto AB, analysts believe Probi AB is more attractive than Vivesto AB.

Probi AB has a beta of 0.595, which suggesting that the stock is 40.504% less volatile than S&P 500. In comparison Vivesto AB has a beta of 33.181, suggesting its more volatile than the S&P 500 by 3218.081%.

Probi AB has a quarterly dividend of $0.12 per share corresponding to a yield of 0%. Vivesto AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Probi AB pays -- of its earnings as a dividend. Vivesto AB pays out -- of its earnings as a dividend.

Probi AB quarterly revenues are --, which are smaller than Vivesto AB quarterly revenues of --. Probi AB's net income of -- is lower than Vivesto AB's net income of -$755.6K. Notably, Probi AB's price-to-earnings ratio is 263.33x while Vivesto AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Probi AB is 6.03x versus -- for Vivesto AB. Usually stocks with elevated PS ratios are considered overvalued.